Skip to main content
. 2020 Apr;40(Suppl 1):S1–S86. doi: 10.14639/0392-100X-suppl.1-40-2020

Table 6.II.

Epidemiological profiles of HPV+/p16+ OPSCC vs HPV-/p16- OPSCC (from Resteghini et al., 2017 21; de Montel et al., 2017 22, mod.).

HPV+/p16+ HPV-/p16-
5-year overall survival (OS) 77% 30%
Local progression Rate
Time to progression
Survival after progression
19%
14 months
13 months
36%
8.5 months
6 months
Distant progression (DP) Time to DP
Multiple sites of DP
Up to 106 months
36%
Up to 33 months
2%